NDASUBCUTANEOUSSOLUTIONPriority Review
Approved
Dec 2022
Lifecycle
Peak
Competitive Pressure
0/100
Mechanism of Action
HIV-1 antiretroviral agent [see ] .
Indications (4)
human immunodeficiency virus type 1 (HIV-1) infection in heavily treatment-experienced adults with multidrug resistant HIV-1 whose current antiretroviral regimen is failing due to resistanceintolerancesafety considerationsHIV-1 infection in heavily treatment-experienced adults with multidrug resistant HIV-1 whose current antiretroviral regimen is failing due to resistance
Loss of Exclusivity
LOE Date
Aug 28, 2041
188 months away
Patent Expiry
Aug 28, 2041
Exclusivity Expiry
Dec 22, 2027